King Pharmaceuticals volatility low; shares near 14-month high
King Pharma is down 15c to $11.30. King recently confirmed Remoxy (Oxycodonew/abuse-deterent properties) should be on track for mid-2010 resubmission following an FDA Complete Response. January and April option implied volatility is at 40; below its 26-week average of 53, according to Track Data, suggesting decreasing price movement. :theflyonthewall.com
News For KG From The Last 14 Days
Check below for free stories on KG the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
Subscribe for More Information